trending Market Intelligence /marketintelligence/en/news-insights/trending/0hoc5a1zno8i-ube_zrxsa2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Aevi Genomic director to retire

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aevi Genomic director to retire

Wilbur Gantz will not stand for re-election to the board of Aevi Genomic Medicine Inc. at the 2018 annual stockholders meeting.

Gantz, who informed the company March 19 that he plans to retire, will continue to serve until his current term expires at the annual meeting.

Gantz has been a director of the Pennsylvania-based clinical stage biopharmaceutical company since October 2013.